AK 0529

Drug Profile

AK 0529

Alternative Names: AK0529

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Ark Biosciences
  • Class Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 17 Jan 2018 Ark Biosciences plans a phase I trial for Respiratory syncytial virus infections (In volunteers) in the UK (NCT03400995)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers, In adults) in Australia (PO, Capsule)
  • 10 Oct 2017 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in China (PO) (NCT03322800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top